Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Depreciation & Amortization (CF) (2020 - 2026)

RxSight filings provide 6 years of Depreciation & Amortization (CF) readings, the most recent being $851000.0 for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 65.24% to $851000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.3 million, a 8.64% decrease, with the full-year FY2025 number at $3.3 million, down 8.64% from a year prior.
  • Depreciation & Amortization (CF) hit $851000.0 in Q4 2025 for RxSight, roughly flat from $854000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.1 million in Q3 2024 to a low of $515000.0 in Q4 2024.
  • Median Depreciation & Amortization (CF) over the past 5 years was $972000.0 (2021), compared with a mean of $938900.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): plummeted 51.0% in 2024 and later skyrocketed 65.24% in 2025.
  • RxSight's Depreciation & Amortization (CF) stood at $1.0 million in 2021, then decreased by 10.44% to $918000.0 in 2022, then rose by 14.49% to $1.1 million in 2023, then plummeted by 51.0% to $515000.0 in 2024, then skyrocketed by 65.24% to $851000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $851000.0 (Q4 2025), $854000.0 (Q3 2025), and $785000.0 (Q2 2025) per Business Quant data.